$12.53
Today
as of Jul 22, 16:48 ET
Last 30 days
Recent Press Releases & News
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Delcath Systems Doses First Patient in Mid-Stage Trial of Hepzato
Delcath Systems Announces First Patient Dosed in Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer
Overview
52-week range
$8.12
$17
48% of range
Avg surprise (last 3)
-6.7%
Avg reaction (last 2)
+11.7%
50% positive
Latest IV / EM
65%
EM ±14.8% · $13 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Thu May 7, 2026 | Mar/2026 | $-0.03 | $-0.01 | -200.0% | -200.0% | -0.2% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $0.02 | — | — | — | — | financials |
| Wed Aug 6, 2025 | Jun/2025 | $0.07 | $0.02 | +250.0% | — | — | earnings |
| Thu May 8, 2025 | Mar/2025 | $0.03 | $0.10 | -70.0% | — | +23.6% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $0.06 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.48 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.45 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-1.14 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.58 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Wed Aug 5, 2026 | Jun/2026 | OTHER | -$0.16 | $0.07 | -328.6% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | $8M |
| Cost of revenue | $4M | — | $3M | $3M | $3M | — | $2M | $2M |
| Gross profit | $21M | — | $18M | $21M | $17M | — | $10M | $6M |
| Operating income | $-2M | — | $-388,000 | $3M | $642,000 | — | $-1M | $-4M |
| Net income | $-1M | — | $830,000 | $3M | $1M | — | $2M | $-14M |
| EPS (diluted) | $-0.03 | — | $0.02 | $0.07 | $0.03 | — | $0.06 | $-0.48 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $41M | $43M | $42M | $34M | $13M | $32M | $8M | $15M |
| Inventory | $10M | $10M | $11M | $11M | $7M | $7M | $7M | $6M |
| Total current assets | $120M | $120M | $121M | $113M | $84M | $74M | $29M | $31M |
| Total assets | $125M | $124M | $124M | $117M | $87M | $77M | $32M | $34M |
| Long-term debt | — | — | — | — | — | — | $2M | $4M |
| Total liabilities | $12M | $12M | $9M | $12M | $7M | $8M | $23M | $30M |
| Total equity | $113M | $111M | $115M | $105M | $80M | $69M | $9M | $4M |